WASHINGTON—The standard and most common approach to randomized clinical trials for moderate to severe IBD that includes randomly assigning responders to placebo in the maintenance phase causes harm to participants, harm that can be minimized or avoided, according to two studies presented at Digestive Disease Week 2024.
“We raise concerns about equipoise in the traditional randomized responder clinical trial designs, especially when a patient with moderate to severe disease responds